



**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 29, 2017

The Corporate Relationship Dept.  
BSE Limited  
1<sup>st</sup> Floor, P.J.Towers  
Dalal Street, Fort  
Mumbai - 400 001  
Scrip Code: 500680

The Manager, Listing Dept.  
The National Stock Exchange of India Ltd.  
Exchange Plaza, 5<sup>th</sup> Floor,  
Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051  
Scrip Symbol: PFIZER

Dear Sirs,

**Sub: Unaudited financial results for the quarter ended June 30, 2017.**

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the unaudited financial results for the quarter ended June 30, 2017, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 12:00 noon and concluded at 3:15 p.m.

Also please find enclosed the Limited Review Report by our Auditors M/s. B S R & Co. LLP, in respect of the above results.

Please take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

Prajeet Nair  
Company Secretary

Encl: A/a

# B S R & Co. LLP

Chartered Accountants

5th Floor, Lodha Excelus,  
Apollo Mills Compound  
N. M. Joshi Marg, Mahalaxmi  
Mumbai - 400 011  
India

Telephone +91 (22) 4345 5300  
Fax +91 (22) 4345 5399

## Limited Review Report on Unaudited Quarterly Financial Results of Pfizer Limited pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors  
Pfizer Limited

We have reviewed the accompanying statement of unaudited financial results for the quarter ended 30 June 2017 ('the Statement') of Pfizer Limited ('the Company'), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Attention is drawn to the fact that the figures for the quarter ended 31 March 2017 as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the end of the third quarter of the previous financial year.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors in their meeting held on 29 July 2017. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 5 July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP  
Chartered Accountants

Firm's Registration No: 101248W/W-100022



Sadashiv Shetty  
Partner

Membership No: 048648

Mumbai  
29 July 2017



**Pfizer Limited**

The Capital, 1802 / 1901,  
Plot No. C - 70, G Block, Bandra Kurla Complex,  
Bandra (East), Mumbai 400 051.  
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

**Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2017**

(₹ in crore except earnings per share)

Particulars	3 months ended 30/06/2017	Preceding 3 months ended 31/03/2017	Corresponding 3 months ended in the previous year 30/06/2016	Previous year ended 31/03/2017
	Unaudited	Audited	Unaudited	Audited
1 Revenue				
(a) Revenue from Operations	432.59	453.17	520.87	2,041.93
(b) Other income	27.27	28.80	21.54	101.16
<b>Total Income</b>	<b>459.86</b>	<b>481.97</b>	<b>542.41</b>	<b>2,143.09</b>
2 Expenses				
(a) Cost of materials consumed	79.73	83.16	108.83	387.54
(b) Purchases of stock-in-trade	121.20	114.35	89.15	424.70
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(58.16)	(35.94)	(1.95)	(15.76)
(d) Excise duty on sales	11.68	15.11	19.64	75.66
(e) Employee benefits expense	80.76	59.88	75.64	303.89
(f) Finance costs	0.18	0.13	0.42	0.96
(g) Depreciation and amortization expense	15.23	16.45	14.98	62.93
(h) Other expenses	120.72	121.96	128.45	516.77
<b>Total Expenses</b>	<b>371.34</b>	<b>375.10</b>	<b>435.16</b>	<b>1,756.69</b>
3 Profit before exceptional items and tax (1 - 2)	88.52	106.87	107.25	386.40
4 Exceptional items (Refer Note 5)	-	-	7.93	130.43
5 Profit before tax (3 + 4)	88.52	106.87	115.18	516.83
6 Tax expense				
(a) Current tax	33.20	30.41	38.16	188.66
(b) Deferred tax	(1.85)	8.42	(3.02)	(8.61)
<b>7 Net Profit for the period / year (5 - 6)</b>	<b>57.17</b>	<b>68.04</b>	<b>80.04</b>	<b>336.78</b>
8 Other Comprehensive Income				
(a) Items that will not be reclassified subsequently to profit or loss	(0.33)	(4.16)	0.51	(5.98)
(b) Income tax related to items that will not be reclassified to profit or loss	0.11	1.44	(0.18)	2.07
<b>Other comprehensive income, net of taxes</b>	<b>(0.22)</b>	<b>(2.72)</b>	<b>0.33</b>	<b>(3.91)</b>
<b>9 Total Comprehensive Income for the period / year (7 + 8)</b>	<b>56.95</b>	<b>65.32</b>	<b>80.37</b>	<b>332.87</b>
10 Paid-up equity share capital (Face Value per share ₹10)	45.75	45.75	45.75	45.75
11 Other equity				2,373.13
12 Earnings per share - Basic and Diluted (of ₹10/- each) (not annualised) Computed on the basis of net profit for the period / year				
(i) before exceptional items (net of tax)	12.50	14.87	16.29	53.60
(ii) after exceptional items	12.50	14.87	17.50	73.61

CIN : L24231MH1950PLC008311


✉ [contactus.india@pfizer.com](mailto:contactus.india@pfizer.com)

🌐 [www.pfizerindia.com](http://www.pfizerindia.com)

**NOTES:**

1. The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its Meeting held on July 29, 2017 and were approved and taken on record at the Meeting of the Board of Directors of the Company held on that date.
2. The financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016. The Reserves (excluding revaluation reserve) as per balance sheet of the previous accounting year ended March 31, 2017, not being mandatory, is not presented.
3. The financial results for quarter ended June 30, 2017 have been subjected to a limited review by the statutory auditors of the Company. The limited review report does not contain any qualifications. The limited review report will be filed with the Stock Exchanges and will also be available on the Company's website - [www.pfizerindia.com](http://www.pfizerindia.com)
4. The figures for the quarter ended March 31, 2017 as reported in these financial results are the balancing figures between the audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the financial year.
5. Exceptional items for the year ended March 31, 2017 includes income from sale of properties and income from assignment of trademarks, net of related expenses. Exceptional item for the quarter ended June 30, 2016 pertains to income from sale of properties, net of related expenses.
6. The Company has only one segment which is 'Pharmaceuticals'. Therefore disclosure relating to segments is not applicable and accordingly not made.

July 29, 2017

For Pfizer Limited  
  
S. Sridhar  
Managing Director